In a pediatric patient using polymyxin B‑hydrocortisone (Neosporin) ear drops at a dose of three drops three times daily for seven days, how common are side effects such as systemic toxicity or tinnitus?

Side Effects of Polymyxin B-Hydrocortisone Ear Drops in Pediatric Patients Are Rare

For a 7-day course of polymyxin B-hydrocortisone ear drops in a pediatric patient with an intact tympanic membrane, side effects are uncommon, with local reactions (pruritus, site irritation) occurring in approximately 5-7% of cases, while systemic toxicity and tinnitus are exceptionally rare with this short duration of therapy.

Overall Safety Profile

The 2014 AAO-HNS guideline on acute otitis externa indicates that adverse events from topical ear drops are generally infrequent 1. The most commonly reported side effects include:

• Pruritus (itching): 5-7%
• Local site reaction: 4-5%
• Other effects (each <2%): rash, discomfort, otalgia, dizziness, vertigo, superinfection, reduced hearing 1

These rates apply to all topical ear preparations studied, including neomycin-polymyxin B-hydrocortisone combinations.

Ototoxicity Risk: Context-Dependent

The risk of ototoxicity (hearing loss, tinnitus) is critically dependent on tympanic membrane integrity:

With Intact Tympanic Membrane (Your Scenario)

• Risk is negligible for a single 7-day course
• The guideline explicitly states: "Clinical experience with topical ototoxic antibiotics in patients with tympanic membrane perforation suggests that hearing loss does not occur after a single short course of therapy" 1
• A prospective study of 358 children receiving polymyxin B-neomycin-dexamethasone drops for 2 weeks post-tympanostomy tube placement showed zero cases of sensorineural hearing loss 2

With Non-Intact Tympanic Membrane (Not Your Case)

• Risk increases with repeated exposure
• One large retrospective study found no increased risk with a single prescription (HR 0.90), but repeated doses (≥2 prescriptions) showed significantly increased risk (HR 1.45) 3
• Severe ototoxicity cases have been reported with prolonged or repetitive use when the middle ear is exposed 4, 5

Systemic Toxicity

Systemic toxicity from topical ear drops is essentially non-existent in standard clinical use. The evidence on polymyxin B toxicity relates almost entirely to:

• Intravenous administration in critically ill patients 6, 7
• Direct middle ear exposure in animal models 5, 8

Topical application to an intact ear canal does not produce clinically significant systemic absorption.

Clinical Pitfalls to Avoid

1. Verify tympanic membrane integrity before prescribing - if there's a perforation or tympanostomy tube, switch to a non-ototoxic fluoroquinolone preparation 1

2. Patient counseling is essential - inform families that:

   • Most symptoms improve within 48-72 hours 1
   • Complete the full 7-day course even if symptoms resolve earlier
   • If the patient tastes the drops, it suggests TM perforation - contact the prescriber 1

3. Duration matters - the 7-day course you prescribed is appropriate and carries minimal risk. Problems arise with prolonged or repeated courses, particularly with middle ear exposure 3

4. Local reactions are self-limiting - the 5-7% who develop pruritus or irritation rarely require discontinuation 1

Bottom Line for Your Patient

With three drops three times daily for seven days in a pediatric patient with an intact tympanic membrane, you can reassure the family that:

• Serious side effects are exceptionally rare
• Local irritation or itching might occur in 1 in 15-20 patients but is typically mild
• Ototoxicity (hearing loss, tinnitus) is not a realistic concern with this single short course
• The medication should be continued for the full 7 days unless unexpected symptoms develop

1, 2